Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
Conditions: Osteosarcoma; Ewing Sarcoma; Rhabdomyosarcoma; Relapsed Pediatric Solid Tumor; Refractory Pediatric Solid Tumor; Melanoma; Hepatoblastoma; Hepatocellular Carcinoma; Neuroblastoma; Wilms Tumor Interventions: Procedure: Cryoablation Therapy; Drug: Nivolumab; Drug: Ipilimumab Sponsors: Children's National Research Institute; Bristol-Myers Squibb Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 31, 2022 Category: Research Source Type: clinical trials
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Conditions: Embryonal Rhabdomyosarcoma; Fusion-Negative Alveolar Rhabdomyosarcoma Interventions: Drug: Cyclophosphamide; Biological: Dactinomycin; Radiation: Radiation Therapy; Drug: Vincristine Sponsors: Children's Oncology Group; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 31, 2022 Category: Research Source Type: clinical trials
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
Conditions: Osteosarcoma; Ewing Sarcoma; Rhabdomyosarcoma; Relapsed Pediatric Solid Tumor; Refractory Pediatric Solid Tumor; Melanoma; Hepatoblastoma; Hepatocellular Carcinoma; Neuroblastoma; Wilms Tumor Interventions: Procedure: Cryoablation Therapy; Drug: Nivolumab; Drug: Ipilimumab Sponsors: Children's National Research Institute; Bristol-Myers Squibb Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 31, 2022 Category: Research Source Type: clinical trials
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Conditions: Embryonal Rhabdomyosarcoma; Fusion-Negative Alveolar Rhabdomyosarcoma Interventions: Drug: Cyclophosphamide; Biological: Dactinomycin; Radiation: Radiation Therapy; Drug: Vincristine Sponsors: Children's Oncology Group; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 31, 2022 Category: Research Source Type: clinical trials
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
Conditions: Osteosarcoma; Ewing Sarcoma; Rhabdomyosarcoma; Relapsed Pediatric Solid Tumor; Refractory Pediatric Solid Tumor; Melanoma; Hepatoblastoma; Hepatocellular Carcinoma; Neuroblastoma; Wilms Tumor Interventions: Procedure: Cryoablation Therapy; Drug: Nivolumab; Drug: Ipilimumab Sponsors: Children's National Research Institute; Bristol-Myers Squibb Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 31, 2022 Category: Research Source Type: clinical trials
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Conditions: Embryonal Rhabdomyosarcoma; Fusion-Negative Alveolar Rhabdomyosarcoma Interventions: Drug: Cyclophosphamide; Biological: Dactinomycin; Radiation: Radiation Therapy; Drug: Vincristine Sponsors: Children's Oncology Group; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 31, 2022 Category: Research Source Type: clinical trials
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
Conditions: Osteosarcoma; Ewing Sarcoma; Rhabdomyosarcoma; Relapsed Pediatric Solid Tumor; Refractory Pediatric Solid Tumor; Melanoma; Hepatoblastoma; Hepatocellular Carcinoma; Neuroblastoma; Wilms Tumor Interventions: Procedure: Cryoablation Therapy; Drug: Nivolumab; Drug: Ipilimumab Sponsors: Children's National Research Institute; Bristol-Myers Squibb Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 31, 2022 Category: Research Source Type: clinical trials
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Conditions: Embryonal Rhabdomyosarcoma; Fusion-Negative Alveolar Rhabdomyosarcoma Interventions: Drug: Cyclophosphamide; Biological: Dactinomycin; Radiation: Radiation Therapy; Drug: Vincristine Sponsors: Children's Oncology Group; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 31, 2022 Category: Research Source Type: clinical trials
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
Conditions: Osteosarcoma; Ewing Sarcoma; Rhabdomyosarcoma; Relapsed Pediatric Solid Tumor; Refractory Pediatric Solid Tumor; Melanoma; Hepatoblastoma; Hepatocellular Carcinoma; Neuroblastoma; Wilms Tumor Interventions: Procedure: Cryoablation Therapy; Drug: Nivolumab; Drug: Ipilimumab Sponsors: Children's National Research Institute; Bristol-Myers Squibb Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 31, 2022 Category: Research Source Type: clinical trials
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Conditions: Embryonal Rhabdomyosarcoma; Fusion-Negative Alveolar Rhabdomyosarcoma Interventions: Drug: Cyclophosphamide; Biological: Dactinomycin; Radiation: Radiation Therapy; Drug: Vincristine Sponsors: Children's Oncology Group; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 31, 2022 Category: Research Source Type: clinical trials
